His tumor had a specific genetic makeup known as mismatch repair-deficient, present in 5% to 10% of all rectal cancer patients, meaning he might qualify for a cutting-edge immunotherapy.
ADVERTORIAL
Menu
ADVERTORIAL
His tumor had a specific genetic makeup known as mismatch repair-deficient, present in 5% to 10% of all rectal cancer patients, meaning he might qualify for a cutting-edge immunotherapy.
DISCLAIMER: THIS IS AN ADVERTISEMENT AND NOT AN ACTUAL NEWS ARTICLE, BLOG, OR CONSUMER PROTECTION UPDATE
